{"organizations": [], "uuid": "85bb618f65a3c8fb0d5b905f133945ce4b999614", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/johnsonjohnson-results/update-1-jj-quarterly-profit-beats-on-demand-for-cancer-drugs-idUSL3N1RU4EG", "country": "US", "domain_rank": 408, "title": "CORRECTED-UPDATE 1-J&J quarterly profit beats on demand for cancer drugs", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T19:09:00.000+03:00", "replies_count": 0, "uuid": "85bb618f65a3c8fb0d5b905f133945ce4b999614"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/johnsonjohnson-results/update-1-jj-quarterly-profit-beats-on-demand-for-cancer-drugs-idUSL3N1RU4EG", "ord_in_thread": 0, "title": "CORRECTED-UPDATE 1-J&J quarterly profit beats on demand for cancer drugs", "locations": [], "entities": {"persons": [{"name": "zytiga", "sentiment": "none"}], "locations": [{"name": "imbruvica", "sentiment": "none"}], "organizations": [{"name": "reuters) - johnson & johnson", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "darzalex", "sentiment": "none"}, {"name": "j&j", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Corrects second paragraph to say J&J&rsquo;s pharmaceuticals sales rose “19.4 pct to $9.84 bln” not “3.8 pct to $3.04 bln”)\nApril 17 (Reuters) - Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.\nJ&J&rsquo;s pharmaceuticals sales rose 19.4 percent to $9.84 billion, driven by sales of its cancer drugs such as Darzalex, Imbruvica and Zytiga that rose 45 percent to $2.31 billion in the quarter.\nJ&J raised its full-year sales forecast to $81.0 billion to $81.8 billion from its previous forecast of $80.6 billion to $81.4 billion.\nExcluding items, the company earned $2.06 per share. Analysts on average were expecting earnings of $2.02 per share, according to Thomson Reuters I/B/E/S.\nSales in the first quarter jumped to $20.01 billion from $17.77 billion a year earlier, beating analysts’ estimates of $19.46 billion.\nNet earnings fell to $4.37 billion, or $1.60 per share, from $4.42 billion, or $1.61 per share, a year earlier.\nShares in the Dow-component were up 1.1 percent to $133.25 before the bell. (Reporting by Manas Mishra in Bengaluru Editing by Supriya Kurane)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T19:09:00.000+03:00", "crawled": "2018-04-18T18:35:01.006+03:00", "highlightTitle": ""}